Credit Suisse’s Dr. Reddy's Laboratories RDY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.08M | Buy |
73,460
+560
| +0.8% | +$8.18K | ﹤0.01% | 2216 |
|
|
2023
Q4 | $1.01M | Sell |
72,900
-5,480
| -7% | -$73.3K | ﹤0.01% | 2323 |
|
|
2023
Q3 | $1.05M | Sell |
78,380
-5,985
| -7% | -$81K | ﹤0.01% | 2271 |
|
|
2023
Q2 | $1.06M | Sell |
84,365
-7,045
| -8% | -$82.2K | ﹤0.01% | 2341 |
|
|
2023
Q1 | $1.04M | Sell |
91,410
-1,775
| -2% | -$19.2K | ﹤0.01% | 2304 |
|
|
2022
Q4 | $964K | Sell |
93,185
-60,170
| -39% | -$649K | ﹤0.01% | 2369 |
|
|
2022
Q3 | $1.6M | Sell |
153,355
-4,270
| -3% | -$45.5K | ﹤0.01% | 1992 |
|
|
2022
Q2 | $1.75M | Sell |
157,625
-6,380
| -4% | -$69.4K | ﹤0.01% | 2014 |
|
|
2022
Q1 | $1.83M | Buy |
164,005
+3,910
| +2% | +$44.3K | ﹤0.01% | 2148 |
|
|
2021
Q4 | $2.1M | Sell |
160,095
-1,665
| -1% | -$21K | ﹤0.01% | 2751 |
|
|
2021
Q3 | $2.11M | Buy |
161,760
+615
| +0.4% | +$8.2K | ﹤0.01% | 2771 |
|
|
2021
Q2 | $2.37M | Sell |
161,145
-2,265
| -1% | -$31.7K | ﹤0.01% | 2734 |
|
|
2021
Q1 | $2.01M | Sell |
163,410
-15,375
| -9% | -$197K | ﹤0.01% | 2822 |
|
|
2020
Q4 | $2.55M | Buy |
178,785
+10,830
| +6% | +$146K | ﹤0.01% | 2642 |
|
|
2020
Q3 | $2.34M | Sell |
167,955
-13,555
| -7% | -$162K | ﹤0.01% | 2315 |
|
|
2020
Q2 | $1.92M | Sell |
181,510
-53,515
| -23% | -$544K | ﹤0.01% | 2410 |
|
|
2020
Q1 | $1.9M | Sell |
235,025
-99,270
| -30% | -$828K | ﹤0.01% | 2176 |
|
|
2019
Q4 | $2.71M | Sell |
334,295
-50,395
| -13% | -$398K | ﹤0.01% | 2368 |
|
|
2019
Q3 | $2.92M | Buy |
384,690
+135,675
| +54% | +$1.01M | ﹤0.01% | 2182 |
|
|
2019
Q2 | $1.87M | Sell |
249,015
-210,380
| -46% | -$1.65M | ﹤0.01% | 2503 |
|
|
2019
Q1 | $3.72M | Sell |
459,395
-130,790
| -22% | -$994K | ﹤0.01% | 1947 |
|
|
2018
Q4 | $4.45M | Sell |
590,185
-273,340
| -32% | -$1.92M | ﹤0.01% | 1654 |
|
|
2018
Q3 | $5.98M | Sell |
863,525
-71,345
| -8% | -$477K | 0.01% | 1586 |
|
|
2018
Q2 | $6.02M | Buy |
934,870
+70,430
| +8% | +$444K | 0.01% | 1608 |
|
|
2018
Q1 | $5.65M | Buy |
864,440
+10,235
| +1% | +$71.7K | 0.01% | 1638 |
|
|
2017
Q4 | $6.42M | Sell |
854,205
-317,775
| -27% | -$2.29M | 0.01% | 1589 |
|
|
2017
Q3 | $8.36M | Buy |
1,171,980
+409,290
| +54% | +$2.94M | 0.01% | 1362 |
|
|
2017
Q2 | $6.43M | Sell |
762,690
-860,390
| -53% | -$7M | 0.01% | 1468 |
|
|
2017
Q1 | $13M | Buy |
1,623,080
+109,695
| +7% | +$947K | 0.01% | 1069 |
|
|
2016
Q4 | $13.7M | Sell |
1,513,385
-280,555
| -16% | -$2.61M | 0.01% | 1023 |
|
|
2016
Q3 | $16.7M | Sell |
1,793,940
-744,440
| -29% | -$7.11M | 0.02% | 915 |
|
|
2016
Q2 | $26M | Sell |
2,538,380
-225,075
| -8% | -$2.06M | 0.03% | 641 |
|
|
2016
Q1 | $25M | Sell |
2,763,455
-68,700
| -2% | -$614K | 0.03% | 628 |
|
|
2015
Q4 | $26.2M | Buy |
2,832,155
+1,077,470
| +61% | +$11.8M | 0.03% | 637 |
|
|
2015
Q3 | $22.4M | Buy |
1,754,685
+322,465
| +23% | +$4.01M | 0.03% | 675 |
|
|
2015
Q2 | $15.8M | Buy |
1,432,220
+122,950
| +9% | +$1.36M | 0.02% | 956 |
|
|
2015
Q1 | $15M | Sell |
1,309,270
-678,690
| -34% | -$7.2M | 0.02% | 968 |
|
|
2014
Q4 | $20.1M | Buy |
1,987,960
+178,070
| +10% | +$1.87M | 0.02% | 879 |
|
|
2014
Q3 | $19M | Sell |
1,809,890
-413,785
| -19% | -$3.89M | 0.02% | 939 |
|
|
2014
Q2 | $19.2M | Sell |
2,223,675
-354,175
| -14% | -$2.98M | 0.02% | 959 |
|
|
2014
Q1 | $22.6M | Sell |
2,577,850
-779,310
| -23% | -$6.78M | 0.02% | 780 |
|
|
2013
Q4 | $27.5M | Buy |
3,357,160
+525,765
| +19% | +$4.16M | 0.03% | 666 |
|
|
2013
Q3 | $21.4M | Sell |
2,831,395
-708,525
| -20% | -$5.15M | 0.02% | 699 |
|
|
2013
Q2 | $26.8M | Buy |
+3,539,920
| New | +$25.8M | 0.03% | 623 |
|
Other funds holding RDY
AIM
Credit Suisse's RDY Position: Q1 2024 in Review
Credit Suisse increased its Dr. Reddy's Laboratories (RDY) stake by 0.77% in Q1 2024, buying an estimated $8.18K and bringing the position to 73,460 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2216.
Credit Suisse first reported a position in RDY in Q2 2013 and has held it in 44 quarters since. The position peaked at $27.5M in Q4 2013. 230 funds tracked by Wall St. Rank hold RDY as of Q1 2024.
- Credit Suisse held 73,460 shares of Dr. Reddy's Laboratories worth $1.08M as of Q1 2024.
- Credit Suisse bought 560 Dr. Reddy's Laboratories shares in Q1 2024, an estimated $8.18K.
- Dr. Reddy's Laboratories made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2216 holding.
- Credit Suisse first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Dr. Reddy's Laboratories position peaked at $27.5M in Q4 2013.
- 230 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.